• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Early Real-World Experiences With Faricimab and Aflibercept 8mg


Peter Kaiser, MD shares his early experiences with faricimab and high dose aflibercept for nAMD and DME. He notes positive outcomes, especially with hard-to-treat patients, and emphasizes the ongoing evaluation of patient response to treatment.


Experts share their clinical experiences using second-generation therapeutics to manage retinal diseases. In early experiences with these drugs for neovascular AMD and DME, the feedback has been generally positive. The use of faricimab, particularly in challenging cases, has shown improvement in around one-third of patients, with another third showing similar outcomes to the previous treatment, aflibercept 2 milligram. High dose aflibercept 8mg has demonstrated efficacy in extending treatment intervals for many patients. While outcomes for the most difficult-to-treat patients are still being assessed by the experts, initial observations suggest improvement, albeit not drastically longer dosing intervals. Overall, the experts anticipate that results will align closely with those of faricimab, with roughly a third of patients experiencing significant improvement and another third seeing comparable outcomes to previous treatments.

This summary was AI-generated and edited for clarity.

Related Videos
Video 5 - "Evolving Role of Steroids and Laser In DME"
Video 3 - "Treating a DME Patient Lost to Follow-Up with a Highly Durable Agent"
Video 2 - "A Case of Neovascular AMD with Persistent Subretinal Fluid"
Video 1 - "A Case of Neovascular AMD With Treatment-Resistant Pigment Epithelium Detachment"
© 2024 MJH Life Sciences

All rights reserved.